You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
智飛生物(300122.SZ):治療用卡介苗進入Ⅲ期臨牀試驗
格隆匯 04-08 18:48

格隆匯4月8日丨智飛生物(300122.SZ)公佈,公司於近日獲悉,由全資子公司安徽智飛龍科馬生物製藥有限公司(以下簡稱“智飛龍科馬”)自主研發的治療用卡介苗進入Ⅲ期臨牀試驗。

智飛龍科馬研發的治療用卡介苗系用卡介菌經培養收集菌體,製備高濃度卡介菌懸液,加入適宜穩定劑凍乾製成的免疫治療劑,用於治療膀胱原位癌以及預防處於Ta或T1期的膀胱乳頭狀瘤經尿道切除術後的復發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account